Caribou Biosciences, Inc. (CRBU)
NASDAQ: CRBU · Real-Time Price · USD
1.850
+0.010 (0.54%)
At close: Aug 22, 2025, 4:00 PM
1.830
-0.020 (-1.08%)
After-hours: Aug 22, 2025, 7:39 PM EDT
Caribou Biosciences Revenue
Caribou Biosciences had revenue of $2.67M in the quarter ending June 30, 2025, a decrease of -23.01%. This brings the company's revenue in the last twelve months to $9.12M, down -72.45% year-over-year. In the year 2024, Caribou Biosciences had annual revenue of $9.99M, down -71.01%.
Revenue (ttm)
$9.12M
Revenue Growth
-72.45%
P/S Ratio
18.63
Revenue / Employee
$62,048
Employees
147
Market Cap
172.28M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.99M | -24.48M | -71.01% |
| Dec 31, 2023 | 34.48M | 20.63M | 148.91% |
| Dec 31, 2022 | 13.85M | 4.25M | 44.31% |
| Dec 31, 2021 | 9.60M | -2.76M | -22.35% |
| Dec 31, 2020 | 12.36M | 6.57M | 113.56% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
CRBU News
- 10 days ago - Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference - GlobeNewsWire
- 3 months ago - Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference - GlobeNewsWire
- 4 months ago - Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs - GlobeNewsWire
- 4 months ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Shareholders to Connect - Accesswire
- 4 months ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Caribou Biosciences, Inc. (CRBU) And Encourages Shareholders to Reach Out - Accesswire
- 4 months ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Shareholders to Learn More About the Investigation - Accesswire